Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico

[-] D-R-AZ | 2 points | Feb 15 2021 16:19:03

Abstract

Objective

There is an urgent need for effective treatments to prevent or attenuate lung and systemic inflammation, endotheliitis, and thrombosis related to COVID-19. The aim of this study was to assess the effectiveness of a multidrug-therapy consisting of Ivermectin, Azithromycin, Montelukast and Acetylsalicylic Acid (“TNR4” therapy) to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.

Design and Methods

A comparative effectiveness study was performed among 768 confirmed SARS-CoV-2 cases aged 18 to 80 years, who received ambulatory care at the Ministry of Health of Tlaxcala. A total of 481 cases received the TNR4 therapy, while 287 received another treatment (comparison group). All participants received home visits and/or phone calls for clinical evaluation during the 14 days after enrollment.

Results

Nearly 85% of cases who received the TNR4 recovered within 14 days compared to 59% in the comparison group. Likelihood of recovery within 14 days was 3.4 times greater among the TNR4 group than in the comparison group. Patients treated with TNR4 had a 75% and 81% lower risk of being hospitalized or death, respectively, than the comparison group.

Conclusions

TNR4 therapy improved recovery and prevented risk of hospitalization and death among ambulatory COVID-19 cases.

Keywords

SARS-CoV-2COVID-19IvermectinAzithromycinMontelukastAcetylsalicylic AcidMexico

[-] bitregister | 3 points | Feb 16 2021 01:56:48

TNR4 had a 75% and 81% lower risk of being hospitalized or death, respectively, than the comparison group.

While this is a comparison study, this is a big, big signal with 768 cases. I am not sure how many more studies are needed to suggest this as standard of care.